MX2017009313A - Formulaciones intravenosas de baclofeno y metodos de tratamiento. - Google Patents

Formulaciones intravenosas de baclofeno y metodos de tratamiento.

Info

Publication number
MX2017009313A
MX2017009313A MX2017009313A MX2017009313A MX2017009313A MX 2017009313 A MX2017009313 A MX 2017009313A MX 2017009313 A MX2017009313 A MX 2017009313A MX 2017009313 A MX2017009313 A MX 2017009313A MX 2017009313 A MX2017009313 A MX 2017009313A
Authority
MX
Mexico
Prior art keywords
treatment methods
intravenous baclofen
baclofen formulations
intravenous
formulations
Prior art date
Application number
MX2017009313A
Other languages
English (en)
Spanish (es)
Inventor
Cloyd Jim
Gomez Adolfo
KRACH Linda
Kriel Robert
Schrogie John
Tucker Stephen
Tuohy Rob
Original Assignee
Allaysis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allaysis Llc filed Critical Allaysis Llc
Publication of MX2017009313A publication Critical patent/MX2017009313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017009313A 2015-01-15 2016-01-15 Formulaciones intravenosas de baclofeno y metodos de tratamiento. MX2017009313A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562103902P 2015-01-15 2015-01-15
PCT/US2016/013672 WO2016115504A1 (en) 2015-01-15 2016-01-15 Intravenous baclofen formulations and treatment methods

Publications (1)

Publication Number Publication Date
MX2017009313A true MX2017009313A (es) 2018-02-09

Family

ID=56406482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009313A MX2017009313A (es) 2015-01-15 2016-01-15 Formulaciones intravenosas de baclofeno y metodos de tratamiento.

Country Status (6)

Country Link
US (5) US10350183B2 (cg-RX-API-DMAC10.html)
EP (1) EP3244884A4 (cg-RX-API-DMAC10.html)
JP (1) JP2018502924A (cg-RX-API-DMAC10.html)
CA (1) CA2974091A1 (cg-RX-API-DMAC10.html)
MX (1) MX2017009313A (cg-RX-API-DMAC10.html)
WO (1) WO2016115504A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3244884A4 (en) 2015-01-15 2018-07-25 Allaysis, LLC Intravenous baclofen formulations and treatment methods
RU2018118617A (ru) * 2015-10-21 2019-11-21 АЛЛЭЙСИС, ЭлЭлСи Баклофен для внутривенного введения и способы лечения
BR112022024966A2 (pt) * 2020-06-22 2023-01-03 Otivio As Métodos para tratar espasticidade usando composições antiespasmódicas e terapia de pressão negativa
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26730A (en) 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
EP0461958B1 (fr) 1990-06-15 1994-09-14 Synthelabo Dérivés de 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanes, leur préparation et leur application en thérapeutique
IT1319275B1 (it) * 1999-10-08 2003-09-26 Neuroscienze S C A R L Uso del baclofen nel trattamento dell'astinenza da etanolo.
US6969383B2 (en) 2002-09-27 2005-11-29 Medtronic, Inc. Method for treating severe tinnitus
US20060089335A1 (en) * 2003-10-14 2006-04-27 Guosong Liu Compositions and methods for enhancing cognitive function and synaptic plasticity
US7824697B2 (en) 2004-07-12 2010-11-02 Board Of Regents, The University Of Texas System High concentration baclofen preparations
DK2083811T3 (en) * 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
US9180108B2 (en) * 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
CA2874737A1 (en) * 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Use of baclofen to treat insomnia
EP3244884A4 (en) 2015-01-15 2018-07-25 Allaysis, LLC Intravenous baclofen formulations and treatment methods

Also Published As

Publication number Publication date
US20200038353A1 (en) 2020-02-06
US20160213631A1 (en) 2016-07-28
US10933042B2 (en) 2021-03-02
US20230248679A1 (en) 2023-08-10
US10350183B2 (en) 2019-07-16
CA2974091A1 (en) 2016-07-21
US12295929B2 (en) 2025-05-13
US20190388373A1 (en) 2019-12-26
EP3244884A4 (en) 2018-07-25
EP3244884A1 (en) 2017-11-22
JP2018502924A (ja) 2018-02-01
WO2016115504A1 (en) 2016-07-21
US20210228520A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
PH12020551397A1 (en) Cot modulators and methods of use thereof
MY202415A (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
PH12016501978A1 (en) Treatment of nafld and nash
MY187540A (en) Compounds active towards bromodomains
BR112017018620A2 (pt) método de administração de tradipitanto, e, tradipitanto.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MX2023011202A (es) Agonistas de receptores alfa de ácido retinoico (rara) para el tratamiento de leucemia mieloide aguda (aml) y síndrome mielodisplásico (mds).
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
TW201613587A (en) Medical treatments based on anamorelin
ZA201703467B (en) Methods of treating ocular conditions
MX395492B (es) Usos terapeuticos de l-4 cloroquinurenina.
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
EP3244884A4 (en) Intravenous baclofen formulations and treatment methods
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
PH12018501166B1 (en) Concentrated gibberellin solution formulations
MX2018004656A (es) Baclofeno intravenoso y metodos de tratamiento.
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
UA103888U (uk) Розчин фенолу для ін'єкцій для лікування хронічного больового синдрому
UA107743C2 (ru) Способ лечения аденокарциномы
EA201691907A1 (ru) Комбинированная терапия кураксинами
UA97431U (uk) Спосіб лікування та профілактики рекурентних депресивних розладів
GEAP201814335A (en) Pharmaceutical composition for the prevention and treatment of diseases associated with elevated inducible nitric oxide synthase